# CCRN's 3<sup>rd</sup> Annual Immunizations Across the Lifespan Conference

OnDemand Webcast <sub>ぷ</sub> 🕏

## Recorded on: Saturday, September 7, 2024

### **LEARNING OBJECTIVES**

- Apply immunizations across the age spectrum
- Summarize NACI recommendations vs unfunded products
- Implement current best practices and explain future developments in immunization in pediatrics, adolescents, and adults
- Identify barriers to vaccine uptake in Canada and provide appropriate counsel and support to patients and families

### SCIENTIFIC PLANNING COMMITTEE



Scott Halperin, MD - Co-Chair Professor, Division of Infectious Diseases Dalhousie University



Peter Lin, MD, CCFP - Co-Chair Director, Primary Care Initiatives, Canadian Heart Research Centre



Christine Palmay, MD, CCFP, FCFP Western University Schulich School of Medicine Physician, Midtown Health & Wellness Clinic



Jia Hu, MD, MSc Adjunct Professor University of Calgary



Sherilyn Houle, BSP, PhD Associate Professor, School of Pharmacy, University of Waterloo



Mike Boivin, BSc. Phm. Clinical Pharmacist Consultant President, CommPharm Consulting Inc.

This program was developed by CCRN and has received an unrestricted educational grant from:

Platinum: GSK, Merck, SanofiGold: CSL SeqirusSilver: Moderna, Valneva, AstraZeneca





For program inquiries, please contact **info@ccrnmd.com** 

Watch the recording on CCRN website Here www.ccrnmd.com > Education > Webcasts

#### 

| AGENDA   |   |   |
|--|---|---|
| 20 MIN<br>1. Determ<br>2. Explain<br>3. Develop<br>20 MIN<br>2. Explain<br>3. Develop  | Influenza Insights: Elevating Vaccination Strategies in Practice<br>ermine who is at elevated risk of influenza related complications<br>ain the current NACI vaccine recommendations for different age groups<br>elop strategies to reduce influenza immunization barriers in practice   | Allison McGeer                              |
| i. Identify ن  | Vaccinate and Protect: Enhancing Pneumococcal Vaccination in Primary Care<br>tify the individuals at elevated risk of pneumococcal infections and complications<br>cribe the current NACI and ACIP pneumococcal vaccine recommendations for different populations<br>ress common questions regarding pneumococcal vaccines  | Alan Kaplan                                 |
| 20 MIN<br>20 MIN<br>20 MIN<br>20 MIN<br>2. Discuss<br>3. Address<br>2. Describ<br>20 MIN<br>2. Discuss<br>3. Address<br>2. Address<br>2. Describ<br>20 MIN<br>2. Discuss<br>3. Address<br>2. Address<br>3.   | Prevent, Protect, Vaccinate: RSV Management in people at risk<br>lain the pathophysiology of RSV and how it affects vulnerable populations<br>cuss the differences between current strategies to protect individuals at risk of RSV complications<br>dress common questions regarding RSV immunization (e.g. coadministration, use in pregnancy) –  | Peter Lin                                   |
| 1. Recall<br>2. Interpre   | Pandemic Perspectives: A Primary Care Update on COVID-19<br>call the latest statistics and trends regarding COVID-19 complication rates, vaccine efficacy, and emerging variants<br>rpret the latest clinical data on COVID-19 vaccines and their implications for protecting patients<br>oly current NACI recommendations for COVID-19 vaccines in your practice   | Jia Hu & Mike Boivin                        |
| 30 MIN   | Question/Answer Session   |   |
| 15 MIN E   | Break   |   |
| <b>20 MIN</b><br><b>1</b> . Descrit<br><b>2</b> . Explain<br><b>3</b> . Discuss<br>(e.g. cl<br><b>4</b> . Cl<br><b>5</b> . Cl<br><b>5</b> . Cl<br><b>6</b> . Cl<br><b>6</b> . Cl<br><b>7</b> . Cl<br><b>7</b> . Cl<br><b>8</b> . Cl<br><b>8</b> . Cl<br><b>9</b> . Cl<br><b>1</b> . Descrit<br><b>1</b> . Discuss<br><b>1</b> . Cl<br><b>1</b> . Cl<br><b>1</b> . Discuss<br><b>1</b> . Cl<br><b>1</b> . Discuss<br><b>1</b> . Discuss<br><b>1</b> . Cl<br><b>1</b> . Discuss<br><b>1</b> . Cl<br><b>1</b> . Discuss<br><b>1</b> . Cl<br><b>1</b> . Discuss<br><b>1</b> . Cl<br><b>1</b> . Cl<br><b>1</b> . Discuss<br><b>1</b> . Cl<br><b>1</b> . Discuss<br><b>1</b> . Discuss<br><b>1</b> . Cl<br><b>1</b> . Cl<br><b>1</b> . Discuss<br><b>1</b> . Cl<br><b>1</b> . Discuss<br><b>1</b> . Cl<br><b>1</b> . Cl<br><b>1</b> . Cl<br><b>1</b> . Cl<br><b>1</b> . Discuss<br><b>1</b> . Cl<br><b>1</b> . | Learning your A, B, C, W, Y's: What you need to know about meningococcal vaccines<br>scribe the current epidemiology and serogroups of N. meningitis within Canada<br>lain the NACI recommendations for meningococcal vaccination for different age groups<br>cuss the importance of meningococcal immunization for different groups seen in practice<br>g. children < 5 years of age, adolescents, and young adults)   | Cora Constantinescu                         |
| CONTRACTOR OF THE CONTRACT OF THE CONTRACTOR OF  | Prevention in Practice: HPV Vaccination Strategies for Primary Care     all the types of cancers associated with Human Papillomavirus (HPV) and the effectiveness of     vaccines in preventing these cancers     cuss current HPV vaccine recommendations for Canadians     bly effective communication techniques to address concerns about HPV vaccination   | Christine Palmay                            |
| 3. Addres  | The Shingles Solution: Herpes Zoster Vaccination Strategies for Clinicians<br>all the epidemiology, risk factors, and complications associated with herpes zoster<br>by the NACI guidelines to identify appropriate candidates for herpes zoster vaccination in a primary care setting<br>dress common questions regarding herpes zoster vaccination. (e.g. immunocompromised patients, use in people v<br>by the guidelines to identify appropriate candidates for herpes zoster vaccination in a primary care setting | Jeffrey Habert<br>with previous bout of HZ) |
| 1. Descril<br>2. Determ<br>travelli  | Vaccines Without Borders: A Clinician's Guide to Travel Health<br>scribe common travel-related conditions that can be prevented with travel vaccines<br>ermine which vaccines could be considered for the prevention of travel-related conditions for individuals<br>velling to common travel destinations<br>cuss the importance of insect-borne disease prevention for travellers to common travel destinations   | Sherilyn Houle                              |
| 30 MIN   | Question/Answer Session   |   |
| 45 MIN   | N Exhibit Break & Satellite Sessions  |   |
| Vaccine N<br>Vaccine N   | Shot of Reality: Tackling Vaccine Questions Through Patient Cases e Management Round Table - Case Discussions:  funded vaccines   | Peter Lin<br>Scott Halperin                 |
| - Trave<br>- Addre<br>- Vacci<br>1. Recall   | avel vaccines - non-resort travel<br>ddressing vaccine hesitancy<br>accine catchup<br>call key considerations, contraindications, and safety considerations for various vaccines.<br>dress common clinician issues regarding vaccine selection and administration.  | Christine Palmay<br>Mike Boivin             |
| 3. Detern  | termine communication strategies that can effectively increase vaccine uptake within practice.<br>The current vaccine recommendations for individuals commonly seen in clinical practice.   |   |
|  | g Remarks   | Scott Halperin                              |
|  |   |   |
|  |   |   |

.



For program inquiries, please contact info@ccrnmd.com

Watch the recording on CCRN website Here www.ccrnmd.com > Education > Webcasts